P3‐159: Cognitive impairment in type 2 diabetic patients using metformin or sulfonylurea: A comparative study

Some studies showed a high prevalence of dementia in diabetic patients. On the other hand chronic hyperinsulinemia is a potential risk factor for Alzheimer dementia. In contrast to sulfonylureas, metformin can control hyperglycemia without inducing hyperinsulinemia. This study aimed to compare cognitive impairment in type II diabetic patients using metformin with those taking glibenclamide. We included two groups of well-controlled type 2 diabetic patients using metformin alone (n=77) or glibenclamide alone (n=79) from Isfahan Endocrine and Metabolism Research Center from Jan 2007 to Jan 2008. Mini mental status (MMS) scale was evaluated and the results were compared between two groups. No significant differences were observed by baseline characteristic (sex, age, level of education, control of diabetes, risk factors, complications of diabetes and duration of disease) between two groups. The mean MMS in metformin and glibenclamide groups was 27.03±3.3 and 26.67±2.9 respectively (p=0.47). No significant differences were observed by baseline characteristic (sex, age, level of education, control of diabetes, risk factors, complications of diabetes and duration of disease) between two groups. The mean MMS in metformin and glibenclamide groups was 27.03±3.3 and 26.67±2.9 respectively (p=0.47).